60 Degrees Pharmaceuticals Completes $1M Private Placement for Operations

Key Facts

In a move reflecting the ongoing capital needs of the biotech sector, 60 Degrees Pharmaceuticals has finalized a private placement of its common stock. According to reports, the company completed the sale of 574,713 shares at a price of $1.74 per share, raising approximately $1 million in gross proceeds. The firm, which specializes in medicines for vector-borne diseases, intends to utilize the capital for working capital and general corporate purposes.

This capital raise was conducted alongside H.C. Wainwright & Co to bolster the company's financial position. The offering included the issuance of Series A and B warrants with specific exercise terms, highlighting a strategic effort to secure operational funding. While the capital is essential for the company's biotech business, such fixed-price placements often present a dilutive risk to existing equity holders.

On the macroeconomic front, market participants are looking toward upcoming US Consumer Confidence data in late July 2026 as a broader indicator of sentiment within the healthcare and small-cap investment landscape.